A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
The presence of P+PBac{XP5.WH5}BSC854 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of the progenitor P{XP}d01071 to be Release 3 genomic coordinate 13372529 on the X chromosome. This corresponds to X:13535903 and 12A9 on the Release 5 map. The insertion site ofthe progenitor PBac{WH}f05834 is Release 5 genomic coordinate X:14049257 , which corresponds to 12E2. Consequently, the breakpoints of Df(1)BSC854 predicted from the Release 5 genomic coordinates of the transposable element insertion sites are X:13535903 ;14049257 and the cytological breakpoints predicted from these coordinates are 12A9;12E2.